



Listing of Claims:

Claims 1-32 (Cancelled).


33. (Currently Amended) An [The] exoprotein inhibitor as set forth in claim 22 further comprising for inhibiting the production of exoproteins from Gram positive bacteria in and around the vagina comprising a non-absorbent substrate for insertion into a vagina being selected from the group consisting of a non-absorbent incontinence device, a barrier birth control device, a tampon applicator, and a douche, the non-absorbent substrate having deposited thereon an effective amount of a first active ingredient, an effective amount of a second active ingredient, and a pharmaceutically active material selected from the group consisting of antimicrobials, antioxidants, anti-parasitic agents, antipruritics, astringents, local anaesthetics, and anti-inflammatory agents, the first active ingredient having the general formula:



wherein R¹ is selected from the group consisting of H, $\text{—}\overset{\text{O}}{\parallel}\text{COR}^5$, —OR^5 , $\text{—R}^6\text{C(O)H}$, $\text{—R}^6\text{COOH}$, $\text{—OR}^6\text{COOH}$, —C(O)NH_2 ,




and NH₂ and salts thereof; R⁵ is a monovalent saturated or unsaturated aliphatic hydrocarbyl moiety; R⁶ is a divalent saturated or unsaturated aliphatic hydrocarbyl moiety; R⁷ is a trivalent saturated or unsaturated aliphatic hydrocarbyl moiety; R⁸ is a monovalent substituted or unsubstituted saturated or unsaturated aliphatic hydrocarbyl moiety which may or may not be interrupted with hetero atoms; R², R³, and R⁴ are independently selected from the group consisting of H, OH, COOH, and -C(O)R⁹; R⁹ is hydrogen or a monovalent saturated or unsaturated aliphatic hydrocarbyl moiety, the second active ingredient having the general formula:




wherein R¹⁰ is a straight or branched alkyl or straight or branched alkenyl having from 8 to about 18 carbon atoms and R¹¹ is selected from the group consisting of an alcohol, a polyalkoxylated sulfosuccinate salt, and wherein the first active ingredient and the second active ingredient are effective in inhibiting the production of exoprotein from Gram positive bacteria.

34. (Currently Amended) An[The] exoprotein inhibitor as set forth in claim 1 further comprising for inhibiting the production of exoproteins from Gram positive bacteria in and around the vagina comprising a non-absorbent substrate for

insertion into a vagina being selected from the group consisting of a non-absorbent incontinence device, a barrier birth control device, a tampon applicator, and a douche, the non-absorbent substrate having deposited thereon an effective amount of a first active ingredient and an effective amount of a second active ingredient, the first active ingredient having the general formula:



wherein R¹ is selected from the group consisting of H, $\text{—}\overset{\text{O}}{\parallel}\text{COR}^5$, —OR^5 , $\text{—R}^6\text{C(O)H}$, $\text{—R}^6\text{COOH}$, $\text{—OR}^6\text{COOH}$, —C(O)NH_2 ,



and NH₂ and salts thereof; R⁵ is a monovalent saturated or unsaturated aliphatic hydrocarbyl moiety; R⁶ is a divalent saturated or unsaturated aliphatic hydrocarbyl moiety; R⁷ is a trivalent saturated or unsaturated aliphatic hydrocarbyl moiety; R⁸ is a monovalent substituted or unsubstituted saturated or unsaturated aliphatic hydrocarbyl moiety which may or may not be interrupted with hetero atoms; R², R³, and R⁴ are independently

selected from the group consisting of H, OH, COOH, and -C(O)R⁹;
R⁹ is hydrogen or a monovalent saturated or unsaturated aliphatic
hydrocarbyl moiety, wherein the first active ingredient is
effective in inhibiting the production of exoprotein from Gram
positive bacteria, and the second active ingredient comprising
an alkyl polyglycoside effective in substantially inhibiting the
production of exoprotein from Gram positive bacteria.

35. (Original) The exoprotein inhibitor as set forth in
claim 34 wherein the alkyl polyglycoside has an alkyl group
having from about 8 to about 18 carbon atoms.


36. (Original) The exoprotein inhibitor as set forth in
claim 35 wherein the alkyl group is a linear alkyl group.

37. (Original) The exoprotein inhibitor as set forth in
claim 35 wherein the alkyl polyglycoside has an alkyl group
having from about 8 to about 14 carbon atoms.

38. (Original) The exoprotein inhibitor as set forth in
claim 34 wherein the alkyl polyglycoside has an HLB of 12 to 14.

39. (Original) The exoprotein inhibitor as set forth in
claim 34 wherein the alkyl polyglycoside has an HLB of 10 to 15.

40. (Original) The exoprotein inhibitor as set forth in
claim 34 wherein the alkyl polyglycoside has the general
formula:



wherein Z is a saccharide residue having 5 or 6 carbon atoms, n is a whole number from 1 to 6, and R¹⁴ is a linear alkyl group having from about 8 to about 18 carbon atoms.

41. (Original) The exoprotein inhibitor as set forth in claim 40 wherein R¹⁴ is a linear alkyl group having from about 8 to about 14 carbon atoms.

42. (Original) The exoprotein inhibitor as set forth in claim 40 wherein R¹⁴ is a linear alkyl group having from about 8 to about 12 carbon atoms.

43. (Original) The exoprotein inhibitor as set forth in claim 34 wherein the second active ingredient is present in an amount of at least about 0.0001 millimoles per gram of non-absorbent substrate.


44. (Original) The exoprotein inhibitor as set forth in claim 34 wherein the second active ingredient is present in an amount of at least about 0.005 millimoles per gram of non-absorbent substrate.

45. (Original) The exoprotein inhibitor as set forth in claim 34 wherein the second active ingredient is present in an amount of at least about 0.005 millimoles per gram of non-absorbent substrate to about 2 millimoles per gram of non-absorbent substrate.


46. (Original) The exoprotein inhibitor as set forth in claim 34 wherein the alkyl polyglycoside is selected from the

group consisting of Glucopon 220, Glucopon 225, Glucopon 425, Glucopon 600, Glucopon 625, and TL 2141.

47. (Currently Amended) An[The] exoprotein inhibitor as set forth in claim 1 further comprising for inhibiting the production of exoproteins from Gram positive bacteria in and around the vagina comprising a non-absorbent substrate for insertion into a vagina being selected from the group consisting of a non-absorbent incontinence device, a barrier birth control device, a tampon applicator, and a douche, the non-absorbent substrate having deposited thereon an effective amount of a first active ingredient and an effective amount of a second active ingredient, the first active ingredient having the general formula:



wherein R^1 is selected from the group consisting of H, $-\overset{\text{O}}{\parallel}\text{COR}^5$, $-\text{OR}^5$, $-\text{R}^6\text{C}(\text{O})\text{H}$, $-\text{R}^6\text{COOH}$, $-\text{OR}^6\text{COOH}$, $-\text{C}(\text{O})\text{NH}_2$,




and NH₂ and salts thereof; R⁵ is a monovalent saturated or unsaturated aliphatic hydrocarbyl moiety; R⁶ is a divalent saturated or unsaturated aliphatic hydrocarbyl moiety; R⁷ is a trivalent saturated or unsaturated aliphatic hydrocarbyl moiety; R⁸ is a monovalent substituted or unsubstituted saturated or unsaturated aliphatic hydrocarbyl moiety which may or may not be interrupted with hetero atoms; R², R³, and R⁴ are independently selected from the group consisting of H, OH, COOH, and -C(O)R⁹; R⁹ is hydrogen or a monovalent saturated or unsaturated aliphatic hydrocarbyl moiety, wherein the first active ingredient is effective in inhibiting the production of exoprotein from Gram positive bacteria, the second active ingredient being selected from the group consisting of glycerol monolaurate and myreth-3-myristate wherein said second active ingredient is effective in substantially inhibiting the production of exoprotein from Gram positive bacteria.


Claims 48-62 (Cancelled).

63. (Currently Amended) An [The] exoprotein inhibitor as set forth in claim 1 further comprising for inhibiting the production of exoproteins from Gram positive bacteria in and around the vagina comprising a non-absorbent substrate for insertion into a vagina being selected from the group consisting of a non-absorbent incontinence device, a barrier birth control device, a tampon applicator, and a douche, the non-absorbent substrate having deposited thereon an effective amount of a first active ingredient and an effective amount of a second active ingredient, the first active ingredient having the general formula:


KCC 4749.2
K-C 16,858.2
PATENT



wherein R^1 is selected from the group consisting of H, $-\overset{\text{O}}{\parallel}\text{COR}^5$,
 $-\text{OR}^5$, $-\text{R}^6\text{C}(\text{O})\text{H}$, $-\text{R}^6\text{COOH}$, $-\text{OR}^6\text{COOH}$, $-\text{C}(\text{O})\text{NH}_2$,



and NH_2 and salts thereof; R^5 is a monovalent saturated or unsaturated aliphatic hydrocarbyl moiety; R^6 is a divalent saturated or unsaturated aliphatic hydrocarbyl moiety; R^7 is a trivalent saturated or unsaturated aliphatic hydrocarbyl moiety; R^8 is a monovalent substituted or unsubstituted saturated or unsaturated aliphatic hydrocarbyl moiety which may or may not be interrupted with hetero atoms; R^2 , R^3 , and R^4 are independently selected from the group consisting of H, OH, COOH, and $-\text{C}(\text{O})\text{R}^9$; R^9 is hydrogen or a monovalent saturated or unsaturated aliphatic hydrocarbyl moiety, wherein the first active ingredient is effective in inhibiting the production of exoprotein from Gram positive bacteria, and the second active ingredient having the general formula:



wherein R^{23} is an alkyl group having from 8 to about 18 carbon atoms and R^{24} , R^{25} , and R^{26} are independently selected from the group consisting of hydrogen and alkyl group having from 1 to about 18 carbon atoms and which can have one or more substitutional moieties selected from the group consisting of hydroxyl, carboxyl, carboxyl salts, and imidazoline wherein the second active ingredient is effective in substantially inhibiting the production of exoprotein from Gram positive bacteria.

64. (Original) The exoprotein inhibitor as set forth in claim 63 wherein the second active ingredient is triethanolamide laureth sulfate.

65. (Original) The exoprotein inhibitor as set forth in claim 63 wherein the second active ingredient is present in an amount of at least about 0.0001 millimoles per gram of non-absorbent substrate.

66. (Original) The exoprotein inhibitor as set forth in claim 63 wherein the second active ingredient is present in an amount of at least about 0.005 millimoles per gram of non-absorbent substrate.

67. (Original) The exoprotein inhibitor as set forth in claim 63 wherein the second active ingredient is present in an

KCC 4749.2
K-C 16,858.2
PATENT

amount from about 0.005 millimoles per gram of non-absorbent substrate to about 0.2 millimoles per gram of non-absorbent substrate.

68. (Original) The exoprotein inhibitor as set forth in claim 63 further comprising a pharmaceutically active material selected from the group consisting of antimicrobials, antioxidants, anti-parasitic agents, antipruritics, astringents, local anaesthetics and anti-inflammatory agents.